Results 1 to 10 of about 144,049 (286)

Atopic Dermatitis

open access: yesAllergy, Asthma & Clinical Immunology
Abstract Atopic dermatitis (AD) is a common, chronic skin disorder that can significantly impact the quality of life (QoL) of affected individuals as well as their families. Although the pathogenesis of the disorder is not yet completely understood, it appears to result from the complex interplay between defects in skin barrier function ...
Kolb L, Villarreal LA, Sathe NC.
europepmc   +8 more sources

Atopic dermatitis [PDF]

open access: yesNature Reviews Disease Primers, 2018
Atopic dermatitis (AD) is the most common chronic inflammatory skin disease, with a lifetime prevalence of up to 20% and substantial effects on quality of life. AD is characterized by intense itch, recurrent eczematous lesions and a fluctuating course.
Stephan, Weidinger   +4 more
exaly   +9 more sources

Atopic Dermatitis [PDF]

open access: yesCutis, 2021
A) Pink scaling plaques and erythematous erosions in the antecubital fossae of a 6-year-old White boy. B) Violaceous, hyperpigmented, nummular plaques on the back and extensor surface of the right arm of a 16-month-old Black girl. C) Atopic dermatitis and follicular prominence/accentuation on the neck of a young Black girl.
Candrice R, Heath, Richard P, Usatine
openaire   +6 more sources

Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry

open access: yesActa Dermato-Venereologica, 2023
Clinical trials showed that upadacitinib, a selective Janus kinase-1 inhibitor, is effective for treatment of moderate-to-severe atopic dermatitis. However, daily practice studies are limited.
Celeste M. Boesjes   +8 more
doaj   +1 more source

Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry

open access: yesActa Dermato-Venereologica, 2021
Dupilumab treatment improves signs, symptoms, and quality of life in patients with moderate-to-severe atopic dermatitis. This study evaluated the impact of dupilumab treatment on absenteeism, presenteeism, and related costs in a large multi-centre cohort
Lieneke F.M. Ariëns   +9 more
doaj   +1 more source

Oral food challenges in children [PDF]

open access: yesKorean Journal of Pediatrics, 2011
Many patients assume that allergic reactions against foods are responsible for triggering or worsening their allergic symptoms. Therefore, it is important to identify patients who would benefit from an elimination diet, while avoiding unnecessary dietary
Hye Yung Yum   +9 more
doaj   +1 more source

High dupilumab levels in tear fluid of atopic dermatitis patients with moderate‐to‐severe ocular surface disease

open access: yesClinical and Translational Allergy, 2023
Background The patho‐mechanism of ocular surface disease (OSD) in dupilumab‐treated atopic dermatitis (AD) patients remains unclear. The aim of this study is to measure dupilumab levels in tear fluid and serum, and relate these findings to the severity ...
Roselie Achten   +13 more
doaj   +1 more source

The course of life of patients with childhood atopic dermatitis [PDF]

open access: yes, 2009
Atopic dermatitis mainly covers the period of infancy to adulthood, an important period in the development of an individual. The impairment of quality of life and the psychological wellbeing of children with atopic dermatitis have been well documented ...
Abeni   +42 more
core   +16 more sources

Prevalence of Isotretinoin Therapy in Adolescents and Young Adults With and Without Atopic Dermatitis: A Nationwide Prescription-based Population Study

open access: yesActa Dermato-Venereologica, 2023
Although isotretinoin has anti-inflammatory and immunomodulatory properties, it can exacerbate atopic dermatitis. National estimates of the extent to which patients with atopic dermatitis are affected by severe acne and isotretinoin tolerability are ...
Cathrine H. Mohn   +4 more
doaj   +1 more source

IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis. [PDF]

open access: yes, 2020
Dupilumab is a fully human antibody to interleukin-4 receptor α that improves the signs and symptoms of moderate to severe atopic dermatitis (AD). To determine the effects of dupilumab on Staphylococcus aureus colonization and microbial diversity on the ...
Ardeleanu, Marius   +16 more
core   +2 more sources

Home - About - Disclaimer - Privacy